These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 29341192)

  • 1. Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in Patients with Moderate to Severe Plaque Psoriasis.
    Yao Z; Hu C; Zhu Y; Xu Z; Randazzo B; Wasfi Y; Chen Y; Sharma A; Zhou H
    J Clin Pharmacol; 2018 May; 58(5):613-627. PubMed ID: 29341192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guselkumab for the treatment of moderate-to-severe plaque psoriasis.
    Yang EJ; Sanchez IM; Beck K; Sekhon S; Wu JJ; Bhutani T
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):333-344. PubMed ID: 29478344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT; Scott LJ
    Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
    Zhu Y; Hu C; Lu M; Liao S; Marini JC; Yohrling J; Yeilding N; Davis HM; Zhou H
    J Clin Pharmacol; 2009 Feb; 49(2):162-75. PubMed ID: 19179295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
    N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies.
    Zhang TT; Ma J; Durbin KR; Montavon T; Lacy SE; Jenkins GJ; Doktor S; Kalvass JC
    AAPS J; 2019 Jun; 21(5):82. PubMed ID: 31250228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
    Nawas Z; Hatch M; Ramos E; Liu M; Tong Y; Peranteau A; Tyring S
    Skin Therapy Lett; 2017 Mar; 22(2):8-10. PubMed ID: 28329405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
    Tran L; Yao Z; Xu Z; Vermeulen A
    Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
    Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
    JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis.
    Timmermann S; Hall A
    Basic Clin Pharmacol Toxicol; 2019 Jul; 125(1):16-25. PubMed ID: 30661290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
    Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
    Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study.
    Salinger DH; Endres CJ; Martin DA; Gibbs MA
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):276-83. PubMed ID: 27128833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.
    Hu C; Wasfi Y; Zhuang Y; Zhou H
    J Pharmacokinet Pharmacodyn; 2014 Jun; 41(3):239-50. PubMed ID: 24852042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
    Chiricozzi A; Costanzo A; Fargnoli MC; Malagoli P; Piaserico S; Amerio P; Argenziano G; Balato N; Bardazzi F; Bianchi L; Carrera CG; Conti A; Dapavo P; De Simone C; Loconsole F; Lo Schiavo A; Malara G; Musumeci ML; Parodi A; Peris K; Prignano F; Rongioletti F; Talamonti M; Potenza C
    Eur J Dermatol; 2021 Feb; 31(1):3-16. PubMed ID: 33648915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab for the treatment of psoriasis.
    Megna M; Balato A; Raimondo A; Balato N
    Expert Opin Biol Ther; 2018 Apr; 18(4):459-468. PubMed ID: 29482382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.